Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients
Aim: To investigate the serum circulating DPP4 activity in patients with COVID-19 disease. Materials & methods: Serum samples from 102 hospitalized COVID-19 patients and 43 post-COVID-19 plasma donors and 39 SARS-CoV-2 naive controls and their medical data were used. Circulating DPP4 activities according to different COVID-19 disease peak severity (WHO) groups at sampling and at peak were assessed. Results: A significant decrease (p < 0.0001) in serum DPP4 activity was found in study groups of higher disease severity. When the circulating DPP4 activity was assessed as a prognostic marker, the logistic regression (p = 0.0023) indicated that the enzyme activity is a predictor of mortality (median 9.5 days before death) with receiver operating characteristic area under the curves of 73.33% (p[area = 0.5] < 0.0001) as single predictor and 83.45% (p[area = 0.5] < 0.0001) in combination with age among hospitalized patients with COVID-19. Conclusion: Decreased circulating DPP4 activity is associated with severe COVID-19 disease and is a strong prognostic biomarker of mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Biomarkers in medicine - 16(2022), 5 vom: 23. Apr., Seite 317-330 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nádasdi, Ákos [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.03.2022 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/bmm-2021-0717 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337266964 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337266964 | ||
| 003 | DE-627 | ||
| 005 | 20231225234027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/bmm-2021-0717 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337266964 | ||
| 035 | |a (NLM)35195023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nádasdi, Ákos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2022 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To investigate the serum circulating DPP4 activity in patients with COVID-19 disease. Materials & methods: Serum samples from 102 hospitalized COVID-19 patients and 43 post-COVID-19 plasma donors and 39 SARS-CoV-2 naive controls and their medical data were used. Circulating DPP4 activities according to different COVID-19 disease peak severity (WHO) groups at sampling and at peak were assessed. Results: A significant decrease (p < 0.0001) in serum DPP4 activity was found in study groups of higher disease severity. When the circulating DPP4 activity was assessed as a prognostic marker, the logistic regression (p = 0.0023) indicated that the enzyme activity is a predictor of mortality (median 9.5 days before death) with receiver operating characteristic area under the curves of 73.33% (p[area = 0.5] < 0.0001) as single predictor and 83.45% (p[area = 0.5] < 0.0001) in combination with age among hospitalized patients with COVID-19. Conclusion: Decreased circulating DPP4 activity is associated with severe COVID-19 disease and is a strong prognostic biomarker of mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a DPP4 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a T2DM | |
| 650 | 4 | |a circulating DPP4 activity | |
| 650 | 4 | |a disease severity | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a prognostic biomarker | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a DPP4 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.14.5 |2 NLM | |
| 650 | 7 | |a Dipeptidyl Peptidase 4 |2 NLM | |
| 650 | 7 | |a EC 3.4.14.5 |2 NLM | |
| 700 | 1 | |a Sinkovits, György |e verfasserin |4 aut | |
| 700 | 1 | |a Bobek, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, Botond |e verfasserin |4 aut | |
| 700 | 1 | |a Förhécz, Zsolt |e verfasserin |4 aut | |
| 700 | 1 | |a Prohászka, Zita Z |e verfasserin |4 aut | |
| 700 | 1 | |a Réti, Marienn |e verfasserin |4 aut | |
| 700 | 1 | |a Arató, Miklós |e verfasserin |4 aut | |
| 700 | 1 | |a Cseh, Gellért |e verfasserin |4 aut | |
| 700 | 1 | |a Masszi, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Merkely, Béla |e verfasserin |4 aut | |
| 700 | 1 | |a Ferdinandy, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Vályi-Nagy, István |e verfasserin |4 aut | |
| 700 | 1 | |a Prohászka, Zoltán |e verfasserin |4 aut | |
| 700 | 1 | |a Firneisz, Gábor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomarkers in medicine |d 2007 |g 16(2022), 5 vom: 23. Apr., Seite 317-330 |w (DE-627)NLM184946271 |x 1752-0371 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:5 |g day:23 |g month:04 |g pages:317-330 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/bmm-2021-0717 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 5 |b 23 |c 04 |h 317-330 | ||